AXGN - AxoGen, Inc.
AxoGen NASDAQ: AXGN President and CEO Michael Dale said the company's growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are expected to be positive but have not yet been quantified.
Axogen, Inc. (AXGN) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
ALACHUA, Fla. and TAMPA, Fla.
Axogen, Inc. (AXGN) Q1 2026 Earnings Call Transcript
AxoGen (AXGN) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to a loss of $0.02 per share a year ago.
ALACHUA, Fla. and TAMPA, Fla.
This healthcare firm develops nerve repair solutions for hospitals and specialists in the U.S. and select global markets.
AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AxoGen (AXGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ALACHUA, Fla. and TAMPA, Fla.
SG Americas Securities LLC boosted its position in AxoGen, Inc. (NASDAQ: AXGN) by 459.9% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 65,480 shares of the medical equipment provider's stock after purchasing an additional 53,786 shares during the quarter. SG Americas
JPMorgan Chase and Co. cut its holdings in shares of AxoGen, Inc. (NASDAQ: AXGN) by 44.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 209,003 shares of the medical equipment provider's stock after selling 170,067 shares during the quarter. JPMorgan Chase and
Exchange Traded Concepts LLC lowered its stake in AxoGen, Inc. (NASDAQ: AXGN) by 45.6% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,897 shares of the medical equipment provider's stock after selling 26,743 shares during the
An Axogen executie reported selling 5,221 shares of Common Stock for a transaction value of approximately $171,000 on March 16, 2026. This represented 1.95% of total holdings as reported in the Form 4; direct holdings, meanwhile, declined from 268,002 to 262,781 shares.
DAFNA Capital Management sold 265,456 AXGN shares in the fourth quarter, with an estimated transaction value of $6.53 million based on quarterly average prices. Meanwhile, the quarter-end position value decreased by $2.36 million, reflecting both trading activity and price movements.
ArrowMark Colorado Holdings LLC grew its stake in AxoGen, Inc. (NASDAQ: AXGN) by 20.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,958,406 shares of the medical equipment provider's stock after purchasing an additional 332,498 shares during the
AxoGen (NASDAQ: AXGN) executives said a newly secured Biologics License Application (BLA) approval has preserved the company's ability to serve patients across a broad range of peripheral nerve repair needs, while also helping address remaining reimbursement and coverage barriers that have affected adoption. BLA label seen as broad, consistent with prior use CEO Mike Dale said
AxoGen (NASDAQ: AXGN) used its presentation at the 47th annual Raymond James Institutional Investors Conference to outline its mission to make restoration of peripheral nerve function an expected standard of care, while also providing updates on growth expectations, reimbursement progress, and the implications of its recently secured FDA Biologics License Application (BLA) for its AVANCE Nerve
Axogen, Inc. (AXGN) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Axogen, Inc. (AXGN) reported strong 21% revenue growth but missed EPS expectations, prompting an 8% share decline and highlighting near-term margin pressures. AXGN is transitioning to a regulated biologics platform with Avance FDA approval, aiming for sustainable growth, 18%+ revenue guidance, and positive free cash flow in 2026. Gross margin compression is driven by one-time regulatory costs and biologics conversion, expected to normalize as biologics pricing and payer coverage expand.